Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?

2016

Brain. 2016 Jul 6. pii: aww169.

Palmqvist S¹, Mattsson N¹, Hansson O².

2024 Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.
2024 Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
2024 Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.
2024 Balance and gait disorders in de novo Parkinson’s disease: support for early rehabilitation.
2024 Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
2024 Altered Empathy Processing in Frontotemporal Dementia.
2024 Multiomics profiling of DNA methylation, microRNA, and mRNA in skeletal muscle from monozygotic twin pairs discordant for type 2 diabetes identifies dysregulated genes controlling metabolism.
2024 Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.
2024 Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.
2024 Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.
2024 GBA1 T369M and Parkinson’s disease – Further evidence of a lack of association in the Swedish population.
2024 A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
2024 Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.
2024 Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
2024 Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.